Lymphoma

Articles

In a phase 1 study of the innate cell engager AFM13, all 4 patients with CD30-positive, relapsed/refractory Hodgkin lymphoma treated with the therapy achieved at least a partial response.

Responses Observed in Entire Cohort of Patients With R/R CD30+ Hodgkin Lymphoma Receiving AFM13

In this article, we present a case of a patient with relapsed Hodgkin lymphoma who responded to salvage chemotherapy incorporating brentuximab vedotin, a novel agent.

Hope After Salvage Therapy Fails: Novel Agents for Relapsed/Refractory Hodgkin Lymphoma

Researchers tested the addition of the T cell–boosting decitabine to anti–PD-1 therapy with camrelizumab among patients with relapsed or refractory classic Hodgkin lymphoma.

Adding the T-Cell Booster Decitabine to Anti–PD-1 Therapy in Hodgkin Lymphoma

Guidelines for cancer screening in survivors of childhood HL may be refined based on the results of this extended follow-up study, say the researchers.

Risk of Future Cancers in Survivors of Childhood Hodgkin Lymphoma

De-escalated treatment may be possible in patients with advanced HL who reach a metabolic response after only 2 cycles of escalated BEACOPP.

Role for PET Imaging in Reducing Tx Toxicity in Advanced Hodgkin Lymphoma?

The FDA has approved brentuximab vedotin (Adcetris) to treat adults with previously untreated stage III or IV cHL, in combination with chemotherapy.

Brentuximab Vedotin Approved for Classical HL 

Recent FDA approval of front-line brentuximab vedotin with chemotherapy in patients with stage III/IV Hodgkin lymphoma offers the first new treatment for this disease in over 40 years.

FDA Approval of Brentuximab Vedotin With Chemo Offers New Hope for Stage III/IV Hodgkin Lymphoma

Researchers report that PD-1/PD-L1 monoclonal blocking antibody allows T cells to remain active and fight malignant evolution, subsequently preventing tumor resistance.

Anti-PD-1 Therapy May Benefit Patients with Hematologic Malignancies

A recent study found that Hodgkin lymphoma patients with active disease achieved clinical responses with tumor-specific T cells that were genetically modified to be rendered resistant to transforming growth factor beta, a cytokine expressed by most human cancers.

Engineered Tumor-Specific T Cells May Help Relapsed Hodgkin Lymphoma Patients

Videos

In this video reviews the management of nodular lymphocyte-predominant Hodgkin lymphoma.

Hodgkin Lymphoma | Topics